News, Editorials, Events, etc.

Xcovery Acquires Meryx

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals December 07, 2021 08:00 AM Eastern Standard Time PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, is proud to announce the acquisition of a majority and controlling stake … Read more

Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research

May 19, 2021 Dr. Samantha Pattenden, Associate Professor within the Division of Chemical Biology and Medicinal Chemistry, and Director of Applied Epigenetic Screening Technologies in the Center for Integrative Chemical Biology and Drug Discovery, and Dr. Ian Davis, Professor, Pediatrics … Read more

Dr. Xiaodong Wang Receives R01 to Develop Novel TYRO3 Inhibitors for Treatment of Cancer

May 14, 2021 Dr. Xiaodong Wang, a Research Professor within the Center for Integrative Chemical Biology and Drug Discovery, and its Director of Medicinal Chemistry was awarded over $1.5 million from NIH along with her collaborator, Douglas Graham, PhD of … Read more

Stephen Frye receives Maximizing Investigators’ Research Award

Tops $2 million, supports small molecule research to identify new approaches to modulating drug target Brittany Jennings March 26, 2021   Each day, Stephen Frye, Ph.D., works to identify pharmacologic approaches to intervene in novel drug targets within stephen_fryethe human … Read more

Spotlight on Dr. Samantha Pattenden and the Pattenden Lab

Dr. Samantha Pattenden, Associate Professor, joined the CICBDD in 2010 as a Postdoctoral Research Associate and in 2015 was promoted to Assistant Professor, Director of Applied Epigenetic Screening Technologies. In 2017 she co-founded Triangle Biotechnology, Inc. with Dr. Paul Dayton … Read more